125 related articles for article (PubMed ID: 31739007)
1. Design of a thrombin inhibitory staphylokinase based plasminogen activator with anti-reocclusion potential.
Arora K; Maheshwari N; Sahni G
Int J Biol Macromol; 2020 Feb; 144():791-800. PubMed ID: 31739007
[TBL] [Abstract][Full Text] [Related]
2. Cloning and purification of an anti-thrombotic, chimeric Staphylokinase in Pichia pastoris.
Vandana ; Kantipudi S; Maheshwari N; Sharma S; Sahni G
Protein Expr Purif; 2019 Oct; 162():1-8. PubMed ID: 31108209
[TBL] [Abstract][Full Text] [Related]
3. Modular design of a novel chimeric protein with combined thrombin inhibitory activity and plasminogen-activating potential.
Wirsching F; Luge C; Schwienhorst A
Mol Genet Metab; 2002 Mar; 75(3):250-9. PubMed ID: 11914037
[TBL] [Abstract][Full Text] [Related]
4. Amino-Terminal Fusion of Epidermal Growth Factor 4,5,6 Domains of Human Thrombomodulin on Streptokinase Confers Anti-Reocclusion Characteristics along with Plasmin-Mediated Clot Specificity.
Maheshwari N; Kantipudi S; Maheshwari A; Arora K; Vandana ; Kwatra N; Sahni G
PLoS One; 2016; 11(3):e0150315. PubMed ID: 26974970
[TBL] [Abstract][Full Text] [Related]
5. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.
Szemraj J; Walkowiak B; Kawecka I; Janiszewska G; Buczko W; Bartkowiak J; Chabielska E
J Thromb Haemost; 2005 Oct; 3(10):2156-65. PubMed ID: 16150047
[TBL] [Abstract][Full Text] [Related]
6. Designing a multifunctional staphylokinase variant (SAK-2RGD-TTI) with appropriate thrombolytic activity in vitro.
Faraji H; Soltani F; Ramezani M; Sadeghnia HR; Nedaeinia R; Moghimi Benhangi H; Mashkani B
Biotechnol Lett; 2020 Jan; 42(1):103-114. PubMed ID: 31686286
[TBL] [Abstract][Full Text] [Related]
7. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots.
Lian Q; Szarka SJ; Ng KK; Wong SL
J Biol Chem; 2003 Jul; 278(29):26677-86. PubMed ID: 12736246
[TBL] [Abstract][Full Text] [Related]
8. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant.
Kowalski M; Brown G; Bieniasz M; Oszajca K; Chabielska E; Pietras T; Szemraj Z; Makandjou-Ola E; Bartkowiak J; Szemraj J
Acta Biochim Pol; 2009; 56(1):41-53. PubMed ID: 19018330
[TBL] [Abstract][Full Text] [Related]
9. Staphylokinase as a plasminogen activator component in recombinant fusion proteins.
Szarka SJ; Sihota EG; Habibi HR; Wong S
Appl Environ Microbiol; 1999 Feb; 65(2):506-13. PubMed ID: 9925575
[TBL] [Abstract][Full Text] [Related]
10. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
[TBL] [Abstract][Full Text] [Related]
11. A fast-acting, modular-structured staphylokinase fusion with Kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy.
Wu SC; Castellino FJ; Wong SL
J Biol Chem; 2003 May; 278(20):18199-206. PubMed ID: 12646571
[TBL] [Abstract][Full Text] [Related]
12. Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations.
Icke C; Schlott B; Ohlenschläger O; Hartmann M; Gührs KH; Glusa E
Mol Pharmacol; 2002 Aug; 62(2):203-9. PubMed ID: 12130670
[TBL] [Abstract][Full Text] [Related]
13. Integration of VEK-30 peptide enhances fibrinolytic properties of staphylokinase.
Bhando T; Singh S; Hade MD; Kaur J; Dikshit KL
Biotechnol Appl Biochem; 2021 Apr; 68(2):213-220. PubMed ID: 32233032
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization of a multifunctional staphylokinase variant with reduced reocclusion, produced from salt inducible E. coli GJ1158.
Pulicherla KK; Kumar A; Gadupudi GS; Kotra SR; Rao KR
Biomed Res Int; 2013; 2013():297305. PubMed ID: 23998121
[TBL] [Abstract][Full Text] [Related]
15. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
Nedaeinia R; Faraji H; Javanmard SH; Ferns GA; Ghayour-Mobarhan M; Goli M; Mashkani B; Nedaeinia M; Haghighi MHH; Ranjbar M
Mol Biol Rep; 2020 Jan; 47(1):819-841. PubMed ID: 31677034
[TBL] [Abstract][Full Text] [Related]
16. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
17. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
18. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor.
Sakai M; Watanuki M; Matsuo O
Biochem Biophys Res Commun; 1989 Jul; 162(2):830-7. PubMed ID: 2527034
[TBL] [Abstract][Full Text] [Related]
20. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
Thromb Haemost; 2009 May; 101(5):867-77. PubMed ID: 19404540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
